my country's multiple anti-coronavirus drugs enter clinical trials

my country's multiple anti-coronavirus drugs enter clinical trials

A variety of anti-coronavirus drugs in my country enter the clinical trial stage

Since the outbreak of the new crown pneumonia, China has continuously researched and explored effective treatment methods in the medical treatment work, and has started the research and development of anti-new crown virus drugs
.

At present, a variety of drugs have completed preclinical research and entered the clinical trial stage

VV116 by Zhong Keyuan Shanghai Institute of Materia Medica, Zhong Keyuan Wuhan Institute of Virology and Zhong Keyuan Xinjiang Institute of Physics and Technology and other domestic research institutions to jointly develop an oral nucleoside anti-virus crown new drug candidates
.

Preclinical pharmacodynamic studies have shown that VV116 has a significant inhibitory effect on the original virus strains and mutant strains of the new coronavirus, such as Delta virus, in vitro

Zhong ASTRI ASTRI Zhong ASTRI ASTRI Zhong ASTRI ASTRI Zhong ASTRI ASTRI

China Ke Xueyuan researcher at Shanghai Institute of Materia Medica Shen Jing Shan: Currently, we now put it (VV116) called drug candidates after preclinical studies are completed, the first in Uzbekistan allowed to carry out clinical trials and the clinical trials are Phase I, II period, III The period is carried out at the same time
.

In China, clinical trials are currently underway, and everyone is looking forward to the clinical data

Chinese Academy of Sciences researcher at Shanghai Institute of Materia Medica Shen Jing Shan: Academy

In the Keyuan within an additional laboratory Shanghai Institute of drugs, researchers are studying the new crown is another anti-viral drug candidates FB2001, the drug is in Keyuan Shanghai Institute of Materia Medica, Shanghai University of Science and Technology and the Joint research and development by Wuhan Institute of Virology and other units of the Academy of Sciences
.

Researcher Liu Hong, the head of the research group, told reporters that they are mainly conducting innovative drug research on the 3CL proteolytic enzyme, a very important target in the replication cycle of the new coronavirus.

Zhong ASTRI ASTRI Zhong ASTRI ASTRI Zhong ASTRI ASTRI

China Kexue Yuan Shanghai Institute of Materia Medica Research Fellow Hong Liu: This compound (FB2001) has a very good inhibitory activity of the enzyme, while the new crown virus also has good antiviral effect
.

In March 2021, a phase I clinical study was conducted in the United States

Chinese Academy of Sciences Shanghai Institute of Materia Medica Research Fellow Hong Liu: Academy

It is understood that R & D work for the new crown anti-viral drugs, Zhong Keyuan Shanghai Institute of Materia Medica has been building in the screening system, virtual screening, high-throughput screening, discovery of lead compounds and subsequent development of small molecule drug candidates have made Very good progress
.

Zhong ASTRI ASTRI

China Kexue Yuan , director of Shanghai Institute of Materia Medica Gilbert: two new drugs are already completed pre-clinical research into clinical one, a clinical study conducted in Uzbekistan in the United States, I believe that clinical Phase I, II, III, continue to verify If it can be proved that our medicine can protect patients with new crowns well, it will be a very important support for patients with new crowns around the world
.

Chinese Academy of Sciences, director of the Shanghai Institute of Materia Medica Gilbert: Academy

In addition, a new drug with China’s independent intellectual property rights, "Prokalamide", has launched three clinical trials in Brazil starting in September 2020.
The hospitalization protection rate was 92%, and the risk of death for severely ill patients was reduced by 78%
.

At present, Prokalamide is conducting Phase III global multi-center clinical trials for the treatment of patients with mild to moderate COVID-19 in the United States, Brazil, South Africa, Argentina, Malaysia, and the Philippines.

Ma Liandong, head of the research and development of procrulamide: procrulamide can inhibit the entry of new coronavirus into cells by two important proteins, one is called ACE2 and the other is called TMPRSS2
.

Prokalamide can regulate the levels of these two proteins and make them drop, so that it prevents the virus from entering the cell to replicate from outside the cell

Ma Liandong, head of Prokalamide R&D: Focus on the new crown pneumonia epidemic